Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease

References

• Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumor necrosis factor-alfa, interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 684–9
   PubMed Web of Science ®Google Scholar
• Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, Mac Dermott RP, et al. Enhanced secretion of tumour necrosis factor-alfa, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174–81
   PubMed Web of Science ®Google Scholar
• Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818–26
   PubMed Web of Science ®Google Scholar
• Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279: G653–9
   PubMed Web of Science ®Google Scholar
• Hogaboam CM, Snider DP, Collins SM. Activation of T lymphocytes by syngeneic murine intestinal smooth muscle cells. Gastroenterology 1996; 110: 1456–66
   PubMed Web of Science ®Google Scholar
• Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myofibroblasts as antigen presenting cells. J Immunol 1992; 149: 661–7
   PubMed Web of Science ®Google Scholar
• Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, et al. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 2004; 53: 85–90
   PubMed Web of Science ®Google Scholar
• Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997; 151: 317–22
   PubMed Web of Science ®Google Scholar
• Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factors: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease?. Int J Biochem Cell Biol 1998; 30: 909–22
   PubMed Web of Science ®Google Scholar
• Nedelec B, Ghahary A, Scott PG, Tredget EE. Control of wound contraction. Basic and clinical features. Hand Clin 2000; 16: 289–302
   PubMed Web of Science ®Google Scholar
• Gelbmann CM, Mestermann S, Gross V, Köllinger M, Schölmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999; 45: 210–7
   PubMed Web of Science ®Google Scholar
• Kelly JK, Preshaw RM. Origin of fistulas in Crohn's disease. J Clin Gastroenterol 1989; 11: 193–6
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–82
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–90
   PubMed Web of Science ®Google Scholar
• Jo M, Kim TH, Soel DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564–7
   PubMed Web of Science ®Google Scholar
• Huang Y, Erdmann N, Peng H, Davis JS, Luo X, Ikezu T, et al. TRAIL-mediated apoptosis in HIV-1 infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol 2006; 177: 2304–13
   PubMed Web of Science ®Google Scholar
• Kamohara H, Matsuyama W, Shimozato O, Abe K, Galligan C, Hashimoto S, et al. Regulation of TRAIL and TRAIL receptor expression in human neutrophils. Immunology 2004; 111: 186–94
   PubMed Web of Science ®Google Scholar
• Rimondi E, Secchiero P, Quaroni A, Zerbinati C, Capitani S, Zauli G. Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. J Cell Physiol 2006; 206: 647–54
   PubMed Web of Science ®Google Scholar
• Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–3
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–8
   PubMed Web of Science ®Google Scholar
• Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693–6
   PubMed Web of Science ®Google Scholar
• Wu G, Burns TF, McDonald ER III, Meng RD, Kao G, Muschel R, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141–3
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386–97
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors. Science 1997; 277: 818–21
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrman I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death- inducing signalling complex (DISC) with the receptor. EMBO J 1995; 14: 5579–88
   PubMed Web of Science ®Google Scholar
• Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417–20
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–7
   PubMed Web of Science ®Google Scholar
• Cremer I, Dieu-Nosjean MC, Maréchal S, Dezutter-Dambuyant C, Goddard S, Adams D, et al. Long-lived immature dendritic cells mediated by TRANCE–RANK interaction. Blood 2002; 100: 3646–55
   PubMed Web of Science ®Google Scholar
• Josien R, Wong BR, Li HL, Steinman RF, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162: 2562–8
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19
   PubMed Web of Science ®Google Scholar
• Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138: 491–8
   PubMed Web of Science ®Google Scholar
• Begue B, Wajant H, Bambou JC, Dubuquoy L, Siegmund D, Beaulieu JF, et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006; 130: 1962–74
   PubMed Web of Science ®Google Scholar
• Heid CA, Stevens J, Livak KJ, Williams PM. Real-time quantitative PCR. Genome Res 1996; 6: 986–94
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Russo P, Beaulieu J, Dionne S, Levy E, Lentze MJ, et al. Susceptibility to FAS-induced apoptosis in human nontumoral enterocyte: role of co-stimulatory factors. J Cell Physiol 1999; 181: 45–54
   PubMed Web of Science ®Google Scholar
• Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755–61
   PubMed Web of Science ®Google Scholar
• Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, et al. Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 2005; 69: 891–901
   PubMed Web of Science ®Google Scholar
• Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P, et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 2004; 279: 22399–403
   PubMed Web of Science ®Google Scholar
• Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1–9
   PubMed Web of Science ®Google Scholar
• Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277: C183–201
   PubMed Web of Science ®Google Scholar
• Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Göke M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 2003; 125: 1341–54
   PubMed Web of Science ®Google Scholar
• Strater J, Walczak H, Pukrop T, von Müller L, Hasel C, Kornmann M, et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infection. Gastroenterology 2002; 122: 659–66
   PubMed Web of Science ®Google Scholar
• Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003; 200: 327–35
   PubMed Web of Science ®Google Scholar
• Miranda-Carus ME, Balsa A, Benito-Miguel M, De Ayala CP, Martin-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004; 50: 2786–93
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003; 171: 1061–9
   PubMed Web of Science ®Google Scholar
• Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005; 54: 1590–6
   PubMed Web of Science ®Google Scholar
• Yurovsky VV. Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol 2003; 28: 225–31
   PubMed Web of Science ®Google Scholar
• Shiiki K, Yoshikawa H, Kinoshita H, Takeda M, Ueno A, Nakajima Y, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Diff 2000; 7: 939–46
   PubMed Web of Science ®Google Scholar
• Matysiak M, Jurewicz A, Jaskolski D, Selmaj K. TRAIL induces death of oligodendrocytes isolated from adult brain. Brain 2000; 125: 2469–80
   Web of Science ®Google Scholar
• Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann NY Acad Sci 2002; 973: 166–80
   PubMed Web of Science ®Google Scholar
• Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation?. Bone 2005; 37: 601–6
   PubMed Web of Science ®Google Scholar
• Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Kamachi M, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblasts-like synovial cells. Clin Exp Immunol 2004; 137: 430–6
   PubMed Web of Science ®Google Scholar
• Holen I, Croucher P, Hamdy F, Eaton C. Osteoprotegerin is a survival factor for human prostate cancer cells. Cancer Res 2002;1619–23.
   PubMed Web of Science ®Google Scholar
• Shipman C, Croucher P. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63: 912–6
   PubMed Web of Science ®Google Scholar